William Blair Estimates Penumbra’s Q1 Earnings (NYSE:PEN)

Penumbra, Inc. (NYSE:PEN) – Equities researchers at William Blair reduced their Q1 2025 EPS estimates for shares of Penumbra in a research report issued on Wednesday, April 2nd. William Blair analyst M. Andrew now anticipates that the company will earn $0.66 per share for the quarter, down from their prior forecast of $0.79. The consensus estimate for Penumbra’s current full-year earnings is $3.67 per share. William Blair also issued estimates for Penumbra’s Q2 2025 earnings at $0.83 EPS, Q2 2025 earnings at $0.83 EPS, Q4 2025 earnings at $1.17 EPS, Q4 2025 earnings at $1.17 EPS, Q1 2026 earnings at $0.99 EPS, Q1 2026 earnings at $0.99 EPS, Q2 2026 earnings at $1.11 EPS, Q3 2026 earnings at $1.30 EPS, Q3 2026 earnings at $1.30 EPS, Q4 2026 earnings at $1.48 EPS, FY2026 earnings at $4.88 EPS and FY2026 earnings at $4.88 EPS.

Penumbra (NYSE:PEN) last released its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The business had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million.

A number of other brokerages have also weighed in on PEN. Canaccord Genuity Group increased their target price on shares of Penumbra from $323.00 to $340.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. JPMorgan Chase & Co. raised their price objective on shares of Penumbra from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. Bank of America began coverage on Penumbra in a research report on Friday, March 14th. They set a “buy” rating and a $320.00 target price on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a report on Wednesday, February 19th. Finally, Piper Sandler reiterated an “overweight” rating and set a $330.00 price objective (up from $250.00) on shares of Penumbra in a research note on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Penumbra presently has a consensus rating of “Moderate Buy” and an average target price of $294.47.

Penumbra Trading Down 4.0 %

Shares of Penumbra stock opened at $262.37 on Friday. Penumbra has a 52-week low of $148.00 and a 52-week high of $310.00. The stock’s 50-day simple moving average is $274.48 and its 200 day simple moving average is $245.61. The stock has a market capitalization of $10.11 billion, a P/E ratio of 771.66, a P/E/G ratio of 2.83 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01.

Hedge Funds Weigh In On Penumbra

Several institutional investors and hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new stake in Penumbra during the fourth quarter valued at about $573,000. State Street Corp lifted its stake in shares of Penumbra by 0.3% in the 3rd quarter. State Street Corp now owns 1,236,671 shares of the company’s stock valued at $240,298,000 after acquiring an additional 3,863 shares during the last quarter. E. Ohman J or Asset Management AB boosted its holdings in Penumbra by 10.4% during the 4th quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company’s stock valued at $5,061,000 after acquiring an additional 2,000 shares during the period. Charles Schwab Investment Management Inc. grew its position in Penumbra by 1.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company’s stock worth $64,493,000 after acquiring an additional 3,807 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Penumbra by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 655,572 shares of the company’s stock worth $127,417,000 after purchasing an additional 11,257 shares during the period. Institutional investors own 88.88% of the company’s stock.

Insider Transactions at Penumbra

In other Penumbra news, Director Thomas Wilder sold 360 shares of the company’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $266.93, for a total value of $96,094.80. Following the completion of the sale, the director now owns 4,692 shares of the company’s stock, valued at $1,252,435.56. This represents a 7.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Maggie Yuen sold 2,000 shares of Penumbra stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $286.00, for a total transaction of $572,000.00. Following the transaction, the chief financial officer now directly owns 15,243 shares in the company, valued at $4,359,498. This trade represents a 11.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 111,236 shares of company stock valued at $31,222,390 in the last quarter. Insiders own 5.00% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.